Related Experiment Video
Updated: May 28, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
T-cell therapies for Epstein-Barr virus-associated lymphomas
Javier El-Bietar1, Catherine Bollard
1Center for Cell and Gene Therapy , Baylor College of Medicine, Texas Children's Hospital, Houston, Texas 77030, USA. jaelbiet@txch.org
Pediatric Hematology and Oncology
|October 26, 2011
Summary
Epstein-Barr virus (EBV) lymphomas vary by viral latency type, highlighting T cell control importance. T-cell therapies show promise for treating these EBV-associated cancers.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Epstein-Barr virus (EBV) causes diverse lymphomas with distinct viral latency patterns.
- Effective T cell-mediated immunity is crucial for controlling EBV-infected B cells.
Purpose of the Study:
- To elucidate the biology of EBV-associated lymphomas.
- To review T cell-based therapeutic strategies for these malignancies.
Main Methods:
- Classification of EBV lymphomas based on latency patterns (Type I, II, III).
- Analysis of T-cell approaches like donor lymphocyte infusions and adoptive T-cell transfer.
Main Results:
- Burkitt's lymphoma (Type I) is least immunogenic; Hodgkin's and non-Hodgkin's lymphomas (Type II) show different antigen expression.
- Posttransplant lymphoproliferative disease and immunodeficiency-associated lymphomas (Type III) are most immunogenic, expressing all latent proteins.
Conclusions:
- T-cell therapies are vital for managing EBV-associated lymphomas.
- Further strategies are needed to enhance the efficacy of T-cell-based treatments.
